APA (7th ed.) Citation

Blomberg, O. S., Kos, K., Spagnuolo, L., Isaeva, O. I., Garner, H., Wellenstein, M. D., . . . de Visser, K. E. (2023). Neoadjuvant immune checkpoint blockade triggers persistent and systemic Treg activation which blunts therapeutic efficacy against metastatic spread of breast tumors. Oncoimmunology, 12(1), 2201147. https://doi.org/10.1080/2162402X.2023.2201147

Chicago Style (17th ed.) Citation

Blomberg, Olga S., et al. "Neoadjuvant Immune Checkpoint Blockade Triggers Persistent and Systemic Treg Activation Which Blunts Therapeutic Efficacy Against Metastatic Spread of Breast Tumors." Oncoimmunology 12, no. 1 (2023): 2201147. https://doi.org/10.1080/2162402X.2023.2201147.

MLA (9th ed.) Citation

Blomberg, Olga S., et al. "Neoadjuvant Immune Checkpoint Blockade Triggers Persistent and Systemic Treg Activation Which Blunts Therapeutic Efficacy Against Metastatic Spread of Breast Tumors." Oncoimmunology, vol. 12, no. 1, 2023, p. 2201147, https://doi.org/10.1080/2162402X.2023.2201147.